Competition record
Perrigo
Deep profile · 2 linked library matters
Perrigo makes store-brand drugs and bought Gerber's Gateway formula plant. A former Perrigo executive also remains in part of Connecticut's generic dermatology case. Those are different dockets.
Overview
Perrigo is a major maker of store-brand medicines and consumer health products. It is the buyer of the Gateway infant-formula plant in the pending capacity case.
The formula theory is that buying spare capacity entrenched store brand and blocked a new entrant. Dismissal was denied on September 18, 2026.
Separately, Connecticut's generic dermatology case continues in part against a former Perrigo executive after a September 11, 2026 order dropped other claims. Do not merge the two dockets.
Competition footprint
Store brand is competition for the national brand, until the capacity to make it is itself scarce.
Generic dermatology claims are drug-by-drug. A partial order is a narrowing.
Neither matter is a judgment against the company.
Consumer & business angle
Retailers hire Perrigo to put a store label on a product. Parents and patients buy the result.
States and pharmacies pay generic prices in the dermatology case.
What to watch
- The Gateway formula claim.
- Which dermatology drugs remain in the Connecticut case.
Markets
store-brand drugs · infant formula · store-brand infant formula · generic dermatology drugs
Also known as: perrigo
Conduct themes
Linked cases in the library
Store-brand infant formula
US · 2026– · ongoing · 6 minA would-be store-brand formula maker survived a motion to dismiss on September 18, 2026. It says Perrigo bought the only plant that could have supplied a new competitor.
Outcome: The acquisition claims remain in the case. The court said alternatives such as Abbott, Mead Johnson, or imports are factual questions, not a reason to dismiss.
Generic dermatology drugs
US · 2026– · ongoing · 6 minConnecticut's generic skin-drug case got narrower on September 11, 2026, and several drug claims are still in court.
Outcome: Clindamycin, certain Desonide conduct, Econazole, Fluocinonide, and Halobetasol claims remain. Other drug claims against that executive were dismissed.